Highlights from EHA – Infographic gallery

July 8, 2024

Download your copy and discover the core insights from EHA Congress, condensed into a dynamic infographic.

Acute promyelocytic LEUKEMIA (APL)

FIRST RESULTS OF THE APOLLO TRIAL:
A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK APL

APL APOLLO Trial

Acute lymphoblastic leukemia (ALL)

BLINATUMOMAB FOR FIRST LINE TREATMENT IN INTERMEDIATE AND HIGH RISK DOWN SYNDROME      B-CELL ALL: INITIAL FINDINGS FROM THE ALLTOGETHER1 DS TRIAL

ALLTogether1 DS Trial

PONATINIB VERSUS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ ALL IN THE PHASE 3 PHALLCON TRIAL: IN-DEPTH RESPONDER ANALYSIS

PhALLCON Trial

Acute Myeloid Leukemia (AML)

MENIN INHIBITORS

AML Clinical Trials Menin Inhibitor

PHASE 1/2 STUDY OF ORAL DECITABINE/ CEDAZURIDINE WITH VENETOCLAX AND GILTERITINIB IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY AML

AML Ven and Gilt Study

COMPLETED DOSE ESCALATION FROM THE FIRST-IN-HUMAN, PHASE 1/2 STUDY OF CD123 NK CELL ENGAGER, SAR443579, IN RELAPSED OR REFRACTORY AML OR HIGH RISK-MYELODYSPLASIA

AML CD123NK Study

ADVERSE PROGNOSTIC IMPACT OF SECONDARY-TYPE MUTATIONS IN ELN 2022 FAVORABLE RISK AML

AML Prognostic Impact